(-0.46%) 5 048.42 points
(-0.98%) 38 086 points
(-0.64%) 15 612 points
(0.35%) $83.86
(-3.36%) $1.583
(0.26%) $2 348.50
(0.74%) $27.56
(1.04%) $930.10
(0.11%) $0.933
(0.12%) $10.96
(0.09%) $0.800
(0.01%) $92.18
@ $31.40
発行日: 11 3月 2024 @ 23:33
リターン: -30.35%
前回のシグナル: 3月 9 - 03:41
前回のシグナル:
リターン: -7.29 %
Live Chart Being Loaded With Signals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma...
Stats | |
---|---|
本日の出来高 | 974 090 |
平均出来高 | 1.26M |
時価総額 | 2.71B |
EPS | $-1.030 ( 2024-02-06 ) |
次の収益日 | ( $-0.0600 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.90 |
ATR14 | $0.0250 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Hamilton James C | Sell | 6 000 | Common Stock |
2024-03-20 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-19 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-18 | Lu Hongbo | Buy | 1 000 | Common Stock |
2024-03-15 | Lu Hongbo | Sell | 0 | Common Stock |
INSIDER POWER |
---|
15.59 |
Last 100 transactions |
Buy: 963 379 | Sell: 694 332 |
ボリューム 相関
Arrowhead Pharmaceuticals 相関
10 最も負の相関 | |
---|---|
GMII | -0.885 |
MTSI | -0.87 |
MEUSW | -0.861 |
ALGM | -0.86 |
DHC | -0.86 |
XOG | -0.852 |
SBBP | -0.85 |
BGCP | -0.849 |
VTRU | -0.849 |
INOD | -0.845 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Arrowhead Pharmaceuticals 相関 - 通貨/商品
Arrowhead Pharmaceuticals 財務諸表
Annual | 2023 |
収益: | $240.74M |
総利益: | $228.24M (94.81 %) |
EPS: | $-1.920 |
Q1 | 2024 |
収益: | $3.55M |
総利益: | $-712 000 (-20.05 %) |
EPS: | $-1.240 |
Q4 | 2023 |
収益: | $16.10M |
総利益: | $12.24M (76.03 %) |
EPS: | $-1.020 |
Q3 | 2023 |
収益: | $15.83M |
総利益: | $12.55M (79.30 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。